[Clinical efficacy of biofeedback and electrical stimulation combined with prostate massage in the treatment of chronic prostatitis / chronic pelvic pain syndrome].

OBJECTIVE: To investigate the effect of biofeedback and electrical stimulation combined with prostate massage on chronic prostatitis /chronic pelvic pain syndrome (CP/CPPS). METHODS: A total of 76 cases of diagnosed CP/CPPS were randomly divided into groups A (n = 20), treated by prostatic massage twice a week, B (n = 20), treated by biofeedback and electrical stimulation 5 times a week, and C (n = 20) treated by biofeedback and electrical stimulation 5 times a week combined with prostatic massage twice a week, all for 14 days. Another 16 cases were included in group D as controls left untreated. NIH-CPSI scores were obtained before and at 30 days after treatment and compared among different groups of the patients. RESULTS: Compared with the baseline, the patients in groups A, B and C showed significant decreases after treatment in the NIH-CPSI scores for pain (ï¼»13.55 ± 2.37ï¼½ vs ï¼»10.85 ± 2.28ï¼½, ï¼»13.40 ± 2.28ï¼½ vs ï¼»10.60 ± 2.23ï¼½, and ï¼»13.70 ± 3.42ï¼½ vs ï¼»8.65 ± 1.69ï¼½), urinary symptoms (ï¼»5.50 ± 1.43ï¼½ vs ï¼»3.65 ± 1.27ï¼½, ï¼»5.65 ± 1.31ï¼½ vs ï¼»3.95 ± 1.28ï¼½, and ï¼»5.40 ± 1.35ï¼½ vs ï¼»2.95 ± 1.28ï¼½), quality of life (ï¼»8.70 ± 1.81ï¼½ vs ï¼»6.90 ± 1.71ï¼½, ï¼»8.90 ± 1.12ï¼½ vs ï¼»5.80 ± 1.85ï¼½, and ï¼»8.95 ± 1.47ï¼½ vs ï¼»4.35 ± 1.53ï¼½) and the total NIH-CPSI scores (ï¼»27.75 ± 2.65ï¼½ vs ï¼»21.40 ± 3.03ï¼½, ï¼»27.95 ± 3.24ï¼½ vs ï¼»20.35 ± 3.95ï¼½, and ï¼»28.05 ± 3.78ï¼½ vs ï¼»15.95 ± 2.41ï¼½) (P < 0.05). Even more remarkable reduction was observed in the total NIH-CPSI scores in group C than in A and B (P < 0.05), but with no statistically significant difference between groups A and B (P > 0.05) or in the control group before and after the treatment (P > 0.05). CONCLUSIONS: Biofeedback and electrical stimulation combined with prostate massage has a synergistic effect on CP/CPPS by alleviating pain and urinary symptoms and improving the quality of life.

[Transurethral holmium laser enucleation of the prostate combined with Jisheng Shenqi Decoction for benign prostatic hyperplasia].

OBJECTIVE: To assess the clinical effects of transurethral holmium laser enucleation of the prostate (HoLEP) combined with Jisheng Shenqi Decoction (HoLEP + JSSD) on BPH. METHODS: This study included 110 BPH patients treated in our hospital from August 2017 to April 2018, who were randomly assigned to receive HoLEP (n = 55) or HoLEP + JSSD (n = 55). We compared the pre- and post-operative IPSS, quality of life (QOL) score, prostate volume, postvoid residual urine volume (PVR), maximum urinary flow rate (Qmax), average urinary flow rate (Qavg) and levels of serum T, E2 and T/E2 as well as postoperative complications between the two groups of patients. RESULTS: After treatment, both IPSS and QOL score were significantly lower in the HoLEP + JSSD than in the HoLEP group (P < 0.05), and so were the prostate volume and PVR (P < 0.05). The Qmax, Qavg and serum T level were significantly higher (P < 0.05) while T/E2 markedly lower in the former than in the latter group (P < 0.05). There were no statistically significant differences between the HoLEP + JSSD and HoLEP groups in the E2 level (P > 0.05) or the total incidence rate of complications postoperatively (21.82% vs 29.09%, P > 0.05). CONCLUSIONS: HoLEP + JSSD can significantly alleviate the lower urinary tract symptoms as well as improve the QOL and bladder and urinary tract functions of BPH patients.

Peptidergic not monoaminergic fibers profusely innervate the young adult human testis.

Numerous studies have reported that intratesticular nerves exert important regulatory effects on the functions of the male gonad; however, as yet little is known about their distribution in the young adult human testis. The purpose of this study was to explore whether peptidergic and adrenergic nerves occur in the male gonad of this age, and, if present, to depict their distribution further. Thirty testes were collected from 15 reproductively healthy donors aged 21-32 years. Antibodies against protein gene product 9.5 (PGP 9.5), neuropeptide Y (NPY), C-terminal flanking peptide of NPY (CPON) and vasoactive intestinal peptide (VIP) were employed for immunohistochemical detection of intratesticular peptidergic nerves, and those against dopamine-beta-hydroxylase (DBH) and 5-hydroxytryptamine (5-HT) for monoaminergic ones. The testicular parenchyma exhibited a rich innervation by PGP 9.5-positive fibers, mainly associated with Leydig cell nests, blood vessels, and seminiferous tubules. Numerous NPY- and CPON-immunoreactive (IR) nerves also appeared in the gonads, but the vast majority were confined to blood vessels. A small number of VIP-IR fibers were detected in some arterioles. By contrast, however, no fibers displaying DBH or 5-HT immunoreactivity were observed within the testis. Additionally, expression of PGP-9.5, NPY, CPON, VIP, DBH and 5-HT was found in Leydig cells, PGP 9.5 in spermatogonia, and NPY and CPON in peritubular myoid cells. Our results suggest that the young adult human testis is devoid of monoaminergic nerves but profusely innervated by peptidergic fibers, which may serve as major neuronal regulators for testicular functions at this age.

[Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer].

OBJECTIVE: To assess the effect of the maximal androgen blockade(MAB) and MAB combined with 125I brachytherapy on prostatic cancer. METHODS: Forty-four patients with prostatic cancer (from 1993 to 2002), 28 at pathologic stage C and 16 at stage D, were analyzed retrospectively. Thirty-five of them were treated by bilateral orchidectomy and anti-androgen drugs, i.e. MAB, and 9 treated by MAB combined with 125I brachytherapy. The survival rates and the variation of serum prostate-specific antigen (PSA) levels between pre- and post-treatment were compared. RESULTS: The level of PSA decreased from 60.3 micrograms/L to 12.1 micrograms/L in 35 patients treated by MAB, and from 72.1 micrograms/L to 3.6 micrograms/L in 9 patients treated by MAB combined with 125I brachytherapy after 6 months. The post-treatment survival rates were 81.3% (26/32, excluding 3 deaths by other diseases) for patients treated by MAB after a mean follow-up of 39.2 (9-84) months and 100% for patients by MAB combined with 125I brachytherapy after a mean follow-up of 13(7-24) months. CONCLUSION: MAB and MAB combined with 125I brachytherapy are effective for patients with prostatic cancer.

Contribution of HOGG1 Ser³²6Cys polymorphism to the development of prostate cancer in smokers: meta-analysis of 2779 cases and 3484 controls.

The HOGG1 gene catalyzes the excision of modified bases and removal of DNA damage adducts. It may play an important role in the prevention of carcinogenesis. Ser³²6Cys polymorphism localizes in exon 7 of the hOGG1 gene. It takes the form of an amino acid substitution, from serine to cysteine, in codon 326. Several epidemiological association studies have been conducted on this polymorphism and its relationship with the risk of prostate cancer. However, results have been conflicting. To resolve this conflict, we conducted a meta-analysis on the association between this polymorphism and prostate cancer, taking into account race, country, sources of controls, and smoking status. A total of nine studies covering 2779 cases and 3484 controls were included in the current meta-analysis. Although no significant association was found between hOGG1 Ser³²6Cys polymorphism and prostate cancer susceptibility in the pooled analysis, individuals with Ser/Cys+Cys/Cys genotypes were found to have greater risk of prostate cancer if they were also smokers (OR = 2.66, 95% CI = 1.58-4.47) rather than non-smokers (OR = 2.18, 95% CI = 1.13-4.19), compared with those with Ser/Ser genotype. In conclusion, our meta-analysis demonstrates that hOGG1 Ser³²6Cys polymorphism is a risk factor for prostate cancer in smokers. Further studies are needed to confirm this relationship.